相关临床试验
2161
196 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
Unknown
14
0.7%
已完成
1365
63.2%
Enrolling By Invitation
35
1.6%
尚未招募
68
3.1%
No Longer Available
2
0.1%
终止
191
8.8%
招募中
274
12.7%
暂停
5
0.2%
Approved For Marketing
2
0.1%
撤回
112
5.2%
进行中（未招募）
93
4.3%
暂无批准数据
- MEDIPAL and JCR announced the first participant has been dosed in the global Phase I/II trial of JR-446 for mucopolysaccharidosis type IIIB, also known as Sanfilippo syndrome type B. - JR-446 is a blood-brain barrier-penetrating alpha-N-acetylglucosaminidase developed by JCR using its proprietary J-Brain Cargo technology, with MEDIPAL holding commercialization rights outside Japan. - MPS IIIB is an ultra-rare lysosomal storage disorder affecting an estimated 500 to 1,000 people worldwide, with no approved treatment currently available. - The open-label trial enrolls patients under six years of age, while a separate Phase I/II trial continues in Japan and JR-446 holds orphan drug designation in the US, EU and Japan.
- Jocasta Neuroscience has secured a direct, exclusive license from UCSF covering α-klotho-based therapeutics, replacing its earlier sublicense held through Unity Biotechnology. - The agreement eliminates all remaining milestone and royalty obligations to Unity, simplifying Jocasta's intellectual property structure ahead of clinical development. - Lead candidate JN-0413, a proprietary subcutaneous α-klotho formulation targeting cognitive decline, is slated for an IND submission in Q4 2026 and Phase I trials in early 2027. - The license spans Alzheimer's, Parkinson's, and ALS, as well as mood disorders and cognitive/motor function enhancement, positioning Jocasta as a leading dedicated recombinant α-klotho program.
- UCSF researchers demonstrated that patient-derived breast cancer organoids can mimic tumor responses to therapies and validate I-SPY2 trial biomarkers. - The study, published in Cell Reports Medicine, used organoids from triple-negative breast cancer to predict resistance to veliparib-platinum chemotherapy. - A drug screen of 386 small-molecule inhibitors on resistant organoids identified ABT-263 combined with cisplatin as a potent alternative strategy. - The findings support organoid modeling as a bridge between clinical biomarkers and precision treatment strategies in breast cancer.
- New HIV patient enrollment fell 59% and viral load testing dropped 33% in Kenya, Uganda, and Tanzania during the first five weeks after January 2025 US funding withdrawal. - The UCSF-led analysis used patient-level data from nearly 103,000 people across 189 clinics, marking the first real-world measurement of the cuts' immediate impact. - Existing patients continued receiving treatment, but the funding pause created a bottleneck that prevented new patients from entering HIV care. - Young people and men, already less likely to access HIV services, experienced the steepest declines in enrollment.
- The PSP Trial Platform (PTP), a landmark platform trial testing multiple drugs simultaneously for progressive supranuclear palsy (PSP), has enrolled its first participant. - Led by UCSF and funded by a five-year grant of up to $75.4 million from the National Institute on Aging, the trial will be conducted at 50 sites nationwide. - The trial aims to enroll 440 participants over two years, with 75% of participants receiving an active drug during the first year to minimize placebo assignment. - Two initial investigational drugs, LM11A-31 from PharmatrophiX and AADvac1 from Axon Neuroscience, are being tested in the platform.
- ADLM 2026 convenes July 26–30 in Anaheim, California, bringing together nearly 17,000 global leaders in clinical laboratory medicine. - Dr. David M. Nathan will open the meeting reflecting on five decades of diabetes research, including his pioneering work establishing hemoglobin A1c as the gold-standard test and the role of GLP-1 in glucose regulation. - Dr. Elizabeth Head will present her 25-year investigation into the Alzheimer's–Down syndrome connection, exploring intervention targets that may inform precision medicine for the broader aging population. - Dr. Arun Wiita will close the conference with mass spectrometry-based discovery of novel cancer biomarkers on blood cancer cell membranes, with potential to yield new immune-based therapies.
- A pilot trial of 21 women with long-standing anorexia nervosa found that three doses of psilocybin combined with talk therapy reduced eating disorder symptoms, with 48% achieving scores comparable to those without an eating disorder at three months. - Participants reported increased motivation to recover that persisted for up to one year after the trial ended, though no meaningful change in body mass index was observed. - The study lacked a control group, and researchers caution that further rigorous trials are needed before psilocybin therapy could become widely available for anorexia. - Anorexia nervosa carries the highest mortality rate of any psychiatric disorder, with affected individuals more than 18 times more likely to die by suicide than the general population.
- A JAMA Network Open study comparing Reddit menopause discussions with over 2 million UCSF electronic health record notes found emotional symptoms discussed online nearly three times as often as in clinical records. - Cognitive symptoms such as brain fog, memory problems, and word-finding difficulty appeared online nearly four times as often as in clinical records, revealing a systematic documentation gap. - Women report rage, panic, and mood shifts being mislabeled as primary psychiatric conditions, leading to unnecessary antidepressant prescriptions and months or years of unnecessary testing. - Researchers argue that because undocumented symptoms are not studied, the next generation of guidelines and drug trials risks being built on an incomplete record of the menopause experience.
- A King's College London study published in Nature Microbiology identifies the IL-1 immune pathway as critical in preventing Candida albicans from spreading and causing fatal disease. - Mice genetically modified to lack IL-1 developed severe, fatal infection when exposed to Candida albicans, confirming IL-1's protective role. - Fungal infections kill more than 2.5 million people annually, with Candida albicans alone responsible for almost one million deaths each year. - The findings could lead to a test identifying at-risk immunocompromised patients and to IL-1-targeting therapies as personalized prevention.
- Regulatory T cells (Tregs) are emerging as "living drugs" capable of restoring immune tolerance rather than merely suppressing symptoms across a broad range of inflammatory diseases. - Early clinical evaluations of Treg therapies in autoimmunity and transplant rejection have demonstrated good safety and tolerability with early signs of clinical benefit. - Next-generation engineered Treg approaches aim to achieve three layers of precision: therapy design, tissue activity and timing, and patient selection based on immune subtype or biomarkers. - Experts emphasize that strategic investment and cross-disciplinary collaboration will be essential to transform tolerance medicine from concept to clinical reality.
